Progesterone-receptor positive breast cancer

This phase 2 trial is testing whether giving a combination of three drugs—neratinib, an aromatase inhibitor (letrozole or anastrozole), and trastuzumab—before surgery can completely eliminate invasive breast cancer in postmenopausal women with ER-positive, HER2-positive breast ca…

This phase I/II platform trial tests several drug combinations, including evorpacept, trastuzumab deruxtecan, zanidatamab, tucatinib, and TTX-MC138, in people with advanced solid tumors, especially metastatic breast cancer. The goal is to find safe and promising regimens that cou…

This early-stage trial tests an experimental oral drug called NKT3964 in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by degrading a protein (CDK2) that helps cancer cells grow. The study has two parts: first, find…

This study is for people with certain types of breast cancer (HER2-positive or triple-negative) who have a complete response to initial drug therapy. It tests whether they can safely skip surgery and only receive radiation, or skip radiation if surgery shows no cancer left. For a…

This study tests whether a special PET/MRI scan using a radioactive tracer (18F-FFNP) can detect early signs that hormone therapy is working in breast cancer. About 53 postmenopausal women with a certain type of breast cancer will get the scan before and after taking anastrozole …

This study is testing a new web and mobile app called SHIELD, designed to support women with hormone receptor-positive breast cancer who are on long-term hormone therapy. The goal is to see if the app is easy to use and helpful for managing treatment. About 30 women will particip…

This study looks at how aromatase inhibitor therapy changes skin quality and self-esteem in breast cancer survivors. Researchers will use skin imaging and surveys to track changes in 35 women starting this hormone therapy. The goal is to better understand and manage these side ef…